Rodrigo Perez-Resendiz
Medical · Los Lunas, NMNPI 1194367862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,118 and has fallen 84.9% since, to $169 in 2025.
Across 67 payments — averaging $26.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$320
- AstraZeneca$232
- GSK$191
- Medtronic$169
- Mylan Specialty L.p.$125
- Organon$94
- plus $654 from 16 others
What the payments were for
- Food & beverage$1,75398%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $320 |
| AstraZeneca | 9 | $232 |
| GSK | 6 | $191 |
| Medtronic | 1 | $169 |
| Mylan Specialty L.p. | 1 | $125 |
| Organon | 2 | $94 |
| Lilly USA, LLC | 4 | $75 |
| AbbVie | 4 | $71 |
| Johnson & Johnson | 4 | $71 |
| Amarin Pharma, Inc. | 3 | $65 |
| Boehringer Ingelheim | 3 | $60 |
| Nestle Healthcare Nutrition Inc. | 3 | $58 |
| Pfizer | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Amgen | 2 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Novartis | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Merck | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,785 in reported general payments places this provider in the 80th percentile of 156 medical providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $57,767 |
| OzempicSemaglutide | 40 | $56,013 |
| TrulicityDulaglutide | 21 | $37,804 |
| FarxigaDapagliflozin Propanediol | 21 | $35,627 |
| EliquisApixaban | 28 | $25,342 |
| JanuviaSitagliptin Phosphate | 19 | $24,670 |
| XareltoRivaroxaban | 16 | $24,075 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $7,312 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $5,261 |
| Novolog FlexpenInsulin Aspart | 14 | $3,394 |
| Atorvastatin Calcium | 278 | $3,221 |
| Gabapentin | 123 | $2,676 |
| Rezvoglar KwikpenInsulin Glargine-Aglr | 15 | $2,564 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,376 |
| Insulin Glargine-Yfgn | 18 | $2,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $60 | $57,76739 claims |
| Novo NordiskOzempic | $320 | $56,01340 claims |
| Lilly USA, LLCTrulicity | $75 | $37,80421 claims |
| AstraZenecaFarxiga | $232 | $35,62721 claims |
| PfizerEliquis | $48 | $25,34228 claims |
| MerckJanuvia | $14 | $24,67019 claims |
| Johnson & JohnsonXarelto | $71 | $24,07516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 medical providers in New Mexico.
Other medical in Los Lunas
- Catherine DelaneyLos Lunas$3K
- Brenda PachecoAcoma$12K
- Paul TapiaAlbuquerque$7K
- Niki NinopoulosAlbuquerque$7K
- William BaconSanta Fe$6K
- Katie JoshiAlbuquerque$6K
- Loretta GonzalesAlbuquerque$5K
- Sarah East BrumanaRoswell$5K
- Ruben FrancoAlbuquerque$4K
- Bradford GwytherAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.